Belpointe Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-836
| Closed | -$81.3K | – | 917 |
|
|
2023
Q1 | $81.3K | Sell |
836
-528
| -39% | -$51.3K | ﹤0.01% | 1431 |
|
|
2022
Q4 | $141K | Sell |
1,364
-92
| -6% | -$9.52K | 0.01% | 1052 |
|
|
2022
Q3 | $124K | Buy |
1,456
+15
| +1% | +$1.28K | 0.01% | 1044 |
|
|
2022
Q2 | $119K | Sell |
1,441
-269
| -16% | -$22.2K | 0.01% | 1031 |
|
|
2022
Q1 | $132K | Buy |
1,710
+38
| +2% | +$2.93K | 0.01% | 1087 |
|
|
2021
Q4 | $148K | Sell |
1,672
-836
| -33% | -$74K | 0.01% | 1019 |
|
|
2021
Q3 | $194K | Sell |
2,508
-102
| -4% | -$7.89K | 0.01% | 869 |
|
|
2021
Q2 | $218K | Sell |
2,610
-66
| -2% | -$5.51K | 0.02% | 803 |
|
|
2021
Q1 | $202K | Buy |
2,676
+201
| +8% | +$15.2K | 0.02% | 747 |
|
|
2020
Q4 | $217K | Buy |
+2,475
| New | +$217K | 0.02% | 670 |
|
|
2020
Q3 | – | Sell |
-1,568
| Closed | -$193K | – | 781 |
|
|
2020
Q2 | $193K | Sell |
1,568
-4,243
| -73% | -$522K | 0.03% | 535 |
|
|
2020
Q1 | $491K | Buy |
+5,811
| New | +$491K | 0.09% | 246 |
|